MY136635A - Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies - Google Patents
Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodiesInfo
- Publication number
- MY136635A MY136635A MYPI20003551A MYPI20003551A MY136635A MY 136635 A MY136635 A MY 136635A MY PI20003551 A MYPI20003551 A MY PI20003551A MY PI20003551 A MYPI20003551 A MY PI20003551A MY 136635 A MY136635 A MY 136635A
- Authority
- MY
- Malaysia
- Prior art keywords
- bone marrow
- antibodies
- patients
- treatment
- marrow involvement
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
THIS INVENTION RELATES TO METHODS OF REDUCING BONE MARROW INVOLVEMENT IN B CELL LYMPHOMA PATIENTS PRIOR TO RADIOIMMUNOTHERAPY BY ADMINISTERING MONOCLONAL ANTIBODIES WHICH TARGET CANCEROUS B CELLS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14828799P | 1999-08-11 | 1999-08-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY136635A true MY136635A (en) | 2008-11-28 |
Family
ID=22525101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI20003551A MY136635A (en) | 1999-08-11 | 2000-08-03 | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1207906A4 (en) |
JP (1) | JP2003513012A (en) |
CN (2) | CN100389825C (en) |
AU (1) | AU784971B2 (en) |
CA (1) | CA2378646A1 (en) |
HK (1) | HK1048945A1 (en) |
MX (1) | MXPA02001398A (en) |
MY (1) | MY136635A (en) |
NO (1) | NO20020639L (en) |
TW (1) | TWI279233B (en) |
WO (1) | WO2001010462A1 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA01011279A (en) | 1999-05-07 | 2002-07-02 | Genentech Inc | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers. |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
PL216630B1 (en) | 2002-10-17 | 2014-04-30 | Genmab As | Human monoclonal antibodies against cd20 |
ES2347241T3 (en) | 2002-12-16 | 2010-10-27 | Genentech, Inc. | VARIATIONS OF IMMUNOGLOBULIN AND ITS USES. |
UA99933C2 (en) | 2003-04-09 | 2012-10-25 | Дженентек, Инк. | Therapy of autoimmune disease in a patient with an inadequate response to tnf-alpha inhibitor |
KR101351122B1 (en) | 2003-05-09 | 2014-01-14 | 듀크 유니버시티 | CD20-Specific Antibodies and Methods of Employing Same |
JP2007536896A (en) | 2003-06-05 | 2007-12-20 | ジェネンテック・インコーポレーテッド | BLYS antagonists and their uses |
US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
CN1993143A (en) | 2004-06-04 | 2007-07-04 | 健泰科生物技术公司 | Method for treating multiple sclerosis |
BR122018016031B8 (en) | 2004-08-04 | 2021-07-27 | Applied Molecular Evolution Inc | process for producing a variant monoclonal antibody with enhanced adcc response |
ES2539250T3 (en) | 2005-07-25 | 2015-06-29 | Emergent Product Development Seattle, Llc | Reduction of B cells through the use of CD37 specific binding and CD20 specific binding molecules |
WO2007014238A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | Single dose use of cd20-specific binding molecules |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
ES2618543T3 (en) | 2005-11-23 | 2017-06-21 | Genentech, Inc. | Methods and compositions related to B lymphocyte assays |
SG172698A1 (en) | 2006-06-12 | 2011-07-28 | Trubion Pharmaceuticals Inc | Single-chain multivalent binding proteins with effector function |
JP5687057B2 (en) | 2007-07-09 | 2015-03-18 | ジェネンテック, インコーポレイテッド | Prevention of disulfide bond reduction during recombinant production of polypeptides. |
DK2233149T3 (en) | 2007-10-16 | 2016-05-17 | Zymogenetics Inc | COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE |
EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
TW201438738A (en) | 2008-09-16 | 2014-10-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
ES2468391T3 (en) * | 2008-12-22 | 2014-06-16 | Millennium Pharmaceuticals, Inc. | Combination of Aurora kinase inhibitors and anti-CD20 antibodies |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
JO3434B1 (en) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders |
KR101822205B1 (en) | 2009-08-11 | 2018-01-25 | 제넨테크, 인크. | Production of proteins in glutamine-free cell culture media |
EP2533810B1 (en) | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
CN104031049A (en) | 2010-02-19 | 2014-09-10 | 米伦纽姆医药公司 | Crystalline Forms Of Aurora Kinase Inhibitor |
WO2012088272A1 (en) * | 2010-12-21 | 2012-06-28 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
JP6360881B2 (en) | 2013-03-22 | 2018-07-18 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Combination of catalytic MTORC1 / 2 inhibitor and selective inhibitor of Aurora A kinase |
CA2970738A1 (en) * | 2015-01-23 | 2016-07-28 | Immunomedics, Inc. | Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma |
WO2016196344A1 (en) | 2015-05-30 | 2016-12-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
PE20180602A1 (en) | 2015-06-24 | 2018-04-09 | Hoffmann La Roche | TRANSFERRIN ANTI-RECEPTOR ANTIBODIES WITH DESIGNED AFFINITY |
MY197562A (en) | 2015-09-21 | 2023-06-23 | Aptevo Res & Development Llc | Cd3 binding polypeptides |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
CN114014936A (en) | 2015-10-02 | 2022-02-08 | 豪夫迈·罗氏有限公司 | Bispecific anti-human CD 20/human transferrin receptor antibodies and methods of use |
JP2019529433A (en) * | 2016-09-16 | 2019-10-17 | ノルディック ナノベクター アルメン アクスイェ セルスカプ | Non-Hodgkin Lymphoma Treatment Method Using Lilotomab and 177Lu-Lilotomab Satetraxetane |
CN108421048B (en) * | 2016-09-28 | 2021-04-20 | 首都医科大学附属北京世纪坛医院 | Nano active carbon targeted drug delivery system, preparation method and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3095175B2 (en) * | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
NZ573838A (en) * | 1998-08-11 | 2011-01-28 | Biogen Idec Inc | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
US6451284B1 (en) * | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
US8557244B1 (en) * | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
-
2000
- 2000-07-25 CN CNB008116644A patent/CN100389825C/en not_active Expired - Lifetime
- 2000-07-25 JP JP2001514978A patent/JP2003513012A/en active Pending
- 2000-07-25 AU AU76260/00A patent/AU784971B2/en not_active Expired
- 2000-07-25 CA CA002378646A patent/CA2378646A1/en not_active Abandoned
- 2000-07-25 WO PCT/US2000/040459 patent/WO2001010462A1/en active Application Filing
- 2000-07-25 CN CNA2008100921383A patent/CN101259270A/en active Pending
- 2000-07-25 MX MXPA02001398A patent/MXPA02001398A/en active IP Right Grant
- 2000-07-25 EP EP00965561A patent/EP1207906A4/en not_active Withdrawn
- 2000-08-03 MY MYPI20003551A patent/MY136635A/en unknown
- 2000-08-10 TW TW089116114A patent/TWI279233B/en not_active IP Right Cessation
-
2002
- 2002-02-08 NO NO20020639A patent/NO20020639L/en not_active Application Discontinuation
-
2003
- 2003-02-18 HK HK03101198.5A patent/HK1048945A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2378646A1 (en) | 2001-02-15 |
AU784971B2 (en) | 2006-08-10 |
CN101259270A (en) | 2008-09-10 |
CN1373671A (en) | 2002-10-09 |
TWI279233B (en) | 2007-04-21 |
EP1207906A1 (en) | 2002-05-29 |
CN100389825C (en) | 2008-05-28 |
NO20020639D0 (en) | 2002-02-08 |
JP2003513012A (en) | 2003-04-08 |
NO20020639L (en) | 2002-04-11 |
HK1048945A1 (en) | 2003-04-25 |
AU7626000A (en) | 2001-03-05 |
EP1207906A4 (en) | 2005-07-06 |
MXPA02001398A (en) | 2002-08-12 |
WO2001010462A1 (en) | 2001-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY136635A (en) | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies | |
HUP0103484A2 (en) | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody | |
AU2003205077A1 (en) | Imaging agents and methods of imaging naaladase of psma | |
CY1110681T1 (en) | ANTI-CD20 TREATMENT FOR PATIENTS receiving BMT Ή PBSC | |
RS20050802A (en) | Combinations for the treatment of diseases involving cell proliferation,migration or apoptosis of myeloma cells,or angiogeneis | |
TW200637574A (en) | Treatment method | |
EP1207904A4 (en) | New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy | |
IL169896A0 (en) | Methods and compositions for administering therapeutic and diagnostic agents | |
UA89350C2 (en) | Humanized antibody that specifically binds human cd20 | |
MY151032A (en) | Treatment of tnf? related disorders | |
WO2006029219A3 (en) | Human monoclonal anti-ctla4 antibodies in cancer treatment | |
DE60028970D1 (en) | AT HER2 BINDING PEPTIDE COMPOUNDS | |
UA84954C2 (en) | Fused pyrimidones usefuel in the treatment and the prevention of cancer | |
MXPA04003674A (en) | Improved use of antitumoral compound in cancer therapy. | |
EA200600921A1 (en) | METHODS AND COMPOSITIONS WITH THE USE OF TALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCER AND OTHER DISEASES | |
IL146125A0 (en) | Novel quinones as disease therapies | |
MX2009010269A (en) | Methods of treating cancer by administering human il-18 combinations. | |
AP2003002785A0 (en) | Treatment of t cell disorders | |
AU2003216109A1 (en) | Therapeutic composition for treatment of cancer by arginine depletion | |
WO2006116185A3 (en) | Methods for the treatment of multiple myeloma | |
WO2007109648A3 (en) | Compositions and methods for modulating store-operated calcium entry | |
MXPA05010575A (en) | Peptabody for cancer treatment. | |
WO2005058251A3 (en) | Hla-dr-specific antibodies, compositions and methods | |
AU2001233912A1 (en) | Diagnosis of breast cancer using bcmp-81 as marker | |
AR029540A1 (en) | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND THERAPY OF CA NCER DE PULMoN |